Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Immunomodulation-mediated anticancer activity of a novel compound from Brugmansia suaveolens leaves

World Congress on Immuno Oncology & Clinical Pharmacy
April 18-19, 2019 | Paris, France

Sunil Kumar, Aditi Gupta, Reena Vohra Saini, Amit Kumar and Neeraj Mahindroo

Himachal Institute of Pharmacy, India Shoolini University, India CSIR-Indian Institute of Integrative Medicine, India

Scientific Tracks Abstracts: Arch Cancer Res

Abstract:

Immunomodulation activity-guided fractionation of ethanol extract of Brugmansia suaveolens leaves was carried out to isolate a novel compound SUPH036-022A (1) by co-culturing test fraction/compound activated PBMC with MCF7 and A549 cancer cell lines. Assessment of immune markers in PBMC and analysis of apoptosis markers and cell cycle was carried out for cancer cells. The structure of the isolated compound was elucidated by spectral analysis. Compound 1 enhanced secretion of immune markers, IL-2 and IFN-γ, from PBMC. Further, compound 1 treated PBMC increased cell death in MCF7 and A549 cell lines and induced ROS production and mitochondrial membrane perturbation, leading to apoptosis. Flow cytometry analysis revealed that compound 1 stimulated PBMC cause five-fold increase in cell cycle perturbations in the sub-G1 stage of cancer cells as compared to negative control, while compound itself had weak cytotoxicity against tested cell lines. Compound 1 increases secretion of immune markers in PBMC inducing apoptosis in co-cultured MCF7 and A549 cancer cells while compound itself had weak cytotoxic activity against these cell lines. Compound 1 is a novel lead for immunomodulation-mediated anticancer activity.

Biography :

Sunil Kumar is a professor at Himachal Institute of Pharmacy India. His interest includes Cancer Biomarkers, Clinical Immunology, Anti-Cancer Drugs, Biochemistry Of Cancer and Immunogenomics. He has published more than 20 papers in reputed journals.

E-mail: suny1435@gmail.com